Clinical Trial Update: Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating adjuvant therapy after surgical resection in biliary tract cancer using a three-drug regimen of capecitabine, lenvatinib, and tisleli…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Lenvatinib (lenvatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fudan University | Conditions: Biliary Tract Cancer | Phase 2 | Status: COMPLETED